RBM10 deletion is associated with resistance to EGFR inhibitors in EGFR-mutant lung cancer, likely due to a reduced BclxS/BclxL ratio, which diminishes apoptosis induced by EGFR inhibitors 15. Here, EGFR is linked to lung carcinoma.